Axsome Therapeutics is trading 4.3% lower at $169.54, with broader biotechnology weakness potentially contributing.

  • The XBI biotechnology ETF is down 2.50%.
  • No clear company-specific announcement or catalyst for October 6 was identified in the available search results.
  • Deutsche Bank’s September 29 price-target reduction to $267 from $280 predates this move and does not establish its cause. Trading volume information was unavailable.